

FRANK J. VEITH INTERNATIONAL SOCIETY

Fourth Annual Meeting

May 1, 2025

University Club
1 W 54th Street, New York City

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and the Frank J. Veith International Society. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Amedco Joint Accreditation #4008163



Physicians (ACCME) Credit Designation

Amedco LLC designates this live activity for a maximum of 9.00 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Society Mission

Non Profit Organization

Purpose of Society

The name of this non-profit society is the Frank J. Veith International Society (FJVIS). The Society is incorporated in the State of New York in the United States of America. Vascular Surgery is defined as the specialty that manages vascular disorders exclusive of those in the heart and brain by medical, endovascular or open operative means.

The objectives of the Frank J. Veith International Society are to help young vascular fellows, surgeons and those with an interest in vascular disease management to advance their careers. The Society promotes education as well as collaboration with a network of upper echelon Vascular Surgery leaders. Together we can preserve and protect the heritage of our Specialty.

Past Presidents

Michael L. Marin, MD (USA) Juan C. Parodi, MD (Argentina) Peter Gloviczki, MD (USA) James C. Stanley, MD (USA)

Executive Board


Peter F. Lawrence, MD - President Alan M. Dietzek, MD, RPVI - Secretary Keith D. Calligaro, MD - Treasurer Neal S. Cayne, MD - Program Chair Enrico Ascher, MD - Executive Director

Society Founder

Enrico Ascher, MD

Society Co-Founders

Keith D. Calligaro, MD
Neal S. Cayne, MD
Alan M. Dietzek, MD, RPVI
Evan C. Lipsitz, MD, MBA
Mahmoud B. Malas, MD, MHS
Michael L. Marin, MD
Manish Mehta, MD, MPH
Clifford M. Sales, MD, MBA
Russell H. Samson, MD, RVT
Michael L. Schwartz, MD
Carlos H. Timaran, MD
Reese A. Wain, MD



THURSDAY, MAY 1, 2025

6:45 - 7:30 Registration and Breakfast

7:30 – 7:33 Opening Remarks: Enrico Ascher, MD, Executive Director, FJVIS

SESSION I

Marfan, Limb Salvage And Thoughtful Topics

Moderators:	Jerry Goldstone, MD, Russell H. Samson, MD, RVT, Richard Schutzer, MD
7:34 – 7:40	Endovascular Repair Of Complex Aortic Aneurysms In Marfan Syndrome In The Post-EVICTUS Era. A Need To Regionalize Care For Complex Vascular Procedures James Black, III, MD
7:41 – 7:47	Preoperative COVID 19 Vaccination Is Associated With Decreased Perioperative Mortality Following Major Vascular Surgery Caron B. Rockman, MD
7:48 – 7:54	When Is Endovascular Therapy The Only Reasonable Approach To Revascularization In Patients With Diabetes Mellitus Palma M. Shaw, MD, MBA, RPVI
7:55 – 8:01	Tumor Boards, Heart Teams, Pseudo-CLI Teams: The Time Has Come For No BS CLTI Teams Matthew T. Menard, MD
8:02 - 8:08	Are Scaffolds Really The Solution For BTK Arteries, Or Do Real World Patients Require Additional Technology? Brian G. DeRubertis, MD
8:09 – 8:15	Adjunctive Techniques For Healing Arterial And Venous Ulcers: Role Of Topical Oxygen Therapy Anil P. Hingorani, MD
8:16 - 8:22	Seeing The Unseen: A Biologic Lens On Aortic Risk Sherene Shalhub, MD, MPH

8:23 – 8:29	Talking And Writing About Unnecessary Endovascular Procedures May Not Be Enough To Stop Harm To Patients. Here Are The Next Steps To Effectively Control Overuse In PAD, Carotid Stenting And PMEG Caitlin W. Hicks, MD, MS
8:30 – 8:36	Have We All Been Drinking The Kool-Aid? The Endovascular Revolution Is Responsible For Unnecessary Or Inappropriate Treatments Russell H. Samson, MD, RVT
8:37 – 8:43	Are The Changes In Surgical Education Positive, Negative Or Neutral? How Can Improvements Be Implemented Linda M. Harris, MD
8:44 – 8:50	Top Five Reasons Why Private Independent Practice Will Soon Be Extinct And Proposals To Save This Endangered Species William P. Shutze, MD
8:51 – 8:57	Surgeons As Hospital Administrators: Don't Say Why Me, Say Try Me! An Antidote To Burnout And An Opportunity To Take Back Control Of Health Care Delivery And Benefit Hospitals Bruce A. Perler, MD, MBA
8:58 - 9:04	Management Of Large Popliteal Artery Aneurysms. This Is How I Do It In France Jacques Busquet, MD
9:05 – 9:11	Mechanical Thrombectomy For Acute Limb Ischemia: One-Year Results From The STRIDE Study Thomas S. Maldonado, MD
9:12 - 9:18	Pros And Cons Of Ligating An A-V Fistula Following Successful Renal Transplantation Larry A. Scher, MD
9:19 – 9:25	SMV/Portal Vein Relationship To The IVC Predicts Ease Of Transfemoral Transcaval PV Access To Facilitate PV Interventions Jacob Cynamon, MD
9:26 – 9:34	Honorary Lecture: Eight Minutes With The American College of Surgeons President- Elect Dr. Anton N. Sidawy
9:35 - 9:52	PANEL DISCUSSION
9:53-10:07	COFFEE BREAK

SESSION II

Carotid, Endoleak, Winners And Presidential Address

Moderators:	Bruce A. Perler, MD, MBA, Thomas S. Maldonado, MD, Reese A. Wain, MD
10:08-10:14	Late Neuro Events Of Asymptomatic vs. Symptomatic Subclavian Steal As Detected By Duplex Ultrasound Ali F. AbuRahma, MD
10:15-10:21	Intravascular Lithotripsy (Shockwave) For Treating Symptomatic Patients With Heavily Calcified Carotid Stenoses In Surgically Inoperable Patients Peter L. Faries, MD
10:22-10:28	Carotid Revascularization: So Many Options! How Do I Justify My Choice Mahmoud B. Malas, MD, MHS

10:29-10:35	Transcarotid TAVRs: A Vascular Surgeon's Role In Alternative Accesses For Aortic Valve Repair Gregg S. Landis, MD
10:36-10:41	New Findings On The Diagnosis, Pathophysiology, And Management Of Carotid Webs Evan C. Lipsitz, MD, MBA
10:42-10:48	These Are The Most Important Clinically Relevant New Advances In Carotid Stenting And TCAR Sean P. Lyden, MD
10:49–10:55	Comments From The Primary Investigator Regarding The Results Of The AAA-SHAPE Study Marc L. Schermerhorn, MD
10:56–11:02	Preoperative Sac Embolization For Index EVAR: Have We Solved The Endoleak Problem Thomas S. Maldonado, MD
11:03–11:09	Surgical Robotics – We Have Missed The Boat. This Is What We Need To Do Now Alan B. Lumsden, MD
	Winners Of The 4th International Innovations Award
11:10-11:16	A Novel Stent-Graft System For Total Transfemoral Endovascular Aortic Arch Repair Wayne W. Zhang, MD
11:17–11:23	ViTAA Aortic Wall Analysis Predicts Aortic Growth And Rupture Randy D. Moore, MD
11:24–11:30	Ultra-Low Profile, Fully Retractable, And Repositionable Transaxillary Endovascular Graft For Infrarenal Aortic Aneurysm Repair Anahita Dua, MD, MS, MBA
11:31–11:40	Introduction To The FJV International Society President By Peter Gloviczki, MD
11:41-12:00	Presidential Address: "The History Of Vascular Surgery – In Rhyme" Peter F. Lawrence, MD
12:00- 1:30	Lunch And Complex Case Presentations
Moderators:	Keith D. Calligaro, MD, Alan M. Dietzek, MD, RPVI

SESSION III

New And Exciting Aortic Topics

Moderators:	Gustavo S. Oderich, MD, Matthew J. Eagleton, MD, Carlos H. Timaran, MD
1:31 – 1:37	How Best To Protect Ourselves From Blindness, Cancer And Osteoporosis During Complex Endovascular Procedures. Does The EggNest System Help Javairiah Fatima, MD
1:38 – 1:44	The United States Aortic Research Consortium (US-ARC) Is Redefining Our Understanding Of Complex Endovascular Aneurysm Repair Andres Schanzer, MD
1:45 – 1:51	Managing The Aortic Bifurcation In Complex Aortic Endografting Matthew J. Eagleton, MD

1:52 – 1:58	Industry, FDA And The Failure Of The US Complex Aortic Environment: It's A Wild West! Michael C. Stoner, MD
1:59 – 2:05	Long-Term Outcomes Following Endovascular Repair Of Post-Dissection Thoracoabdominal Aortic Aneurysms Carlos H. Timaran, MD
2:06 – 2:12	GREAT Registry: 10-Year Follow-Up Of Endovascular Aortic Care Ross Milner, MD
2:13 – 2:19	Outcomes Of Fenestrated Branched Endovascular Repair Of Complex Aortic Aneurysms Can Be Improved By Increasing Clinical Experience And Changes In Practice Protocols Gustavo S. Oderich, MD
2:20 – 2:26	The TAMBE Device For TAAA: Indications, Results And Lessons Learned Since FDA Approval Luis A. Sanchez, MD
2:27 – 2:33	Evolution In The Management Of Blunt Thoracic Aortic Injury: When NOT To Intervene And What Are The Long-Term Results Apostolos K. Tassiopoulos, MD
2:34 – 2:40	Zone Zero Endovascular Aortic Arch Repair Is A Viable Option Compared To Conventional Open Repair James F. McKinsey, MD
2:41 – 2:47	Technical Strategies For Safely Performing Open Complex Abdominal Aortic Aneurysm Repair Manju Kalra, MBBS
2:48 – 2:54	Midterm Clinical Results Of Fenestrated vs. Chimney Grafts For The Treatment Of Para-Renal Aneurysms Samuel R. Money, MD, MBA
2:55 – 3:01	Can TAMBE Eliminate Surgery For The Visceral Aorta? Should We Stop Teaching Open Procedures For The Visceral Aorta? Michel Makaroun, MD
3:02 – 3:14	PANEL DISCUSSION
3:15 – 3:30	COFFEE BREAK

SESSION IV

Visceral Aneurysms, AI, Veins And Major Contributions

Moderators:	James C. Stanley, MD, Michael L. Marin, MD, Peter Gloviczki, MD
3:31 – 3:37	Contemporary Management Of Acute Mesenteric Ischemia Timur P. Sarac, MD
3:38 – 3:44	A Conundrum: Treatment Of Gastroduodenal, Pancreaticoduodenal, Jejunal, Ileal, And Inferior Mesenteric Arterial Aneurysms Arising In Collaterals That Evolve From Occlusive Lesions Of The Celiac And Superior Mesenteric Arteries James C. Stanley, MD

3:45 – 3:51	Management Of Visceral Aneurysms: The Everlasting Dilemma Between Open vs. Endo Repair Rabih A. Chaer, MD
3:52 – 3:58	Vascular Reconstructions For Pancreatic Cancer Require Experience, Innovation And Commitment: Lessons Learned Karan Garg, MD
3:59 – 4:05	Artificial Intelligence Application To Vascular Care: Is It A Blessing Or A Curse? Edouard Aboiam, MD
4:06 - 4:12	Venous Hypertension: The Use Of CEAP To Guide Treatment Jose I. Almeida, MD, RVT
4:13 – 4:19	Managing Advanced Venous Disease – An Evolving Landscape And Recognition Of Mortality Mikel Sadek, MD
4:20 – 4:26	Tandem Vein Tumescent (TVT) During Polidocanol Endovenous Microfoam Ablation A Novel Technique To Expand Indications And Limit Product Volume Natalie A. Marks, MD, RPVI, RVT
4:27 – 4:33	Comparative Effectiveness Of Non-Compounded Polidocanol 1% Endovenous Microfoam (Varithena) Ablation vs. Endovenous Thermal Ablation Utilizing A Systematic Review And Network Meta-Analysis Lowell S. Kabnick, MD
4:34 – 4:40	Why Should We Use Venoactive Compounds For Chronic Venous Disease When They Are Not Approved By The FDA? Monika Gloviczki, MD, PhD
4:41 – 4:47	Pulmonary Embolism Following Lower Extremity Venous Ablation Is Not Common But It Can Happen. Should This Be Part Of The Informed Consent Rebeca Reachi, MD
4:48 – 4:54	Limitations Of A Randomized Clinical Trial. It Is Not Always The Gold-Standard! Kenneth Ouriel, MD, MBA
4:55 – 5:01	Value Of Vascular Surgeons When Expanding The Scope Of Vascular Practice: Helps Patients And The Bottom Line R. Clement Darling III, MD
5:02 – 5:08	Sony, Porsche And Vascular Surgery In The 21st Century: Revisited 29 Years Later Jerry Goldstone, MD
5:09 – 5:15	My Most Significant Contributions To Vascular Surgery - Many Of Which Have Been Forgotten! Frank J. Veith, MD
5:16 - 5:30	PANEL DISCUSSION
5:31 – 5:35	Closing Remarks Enrico Ascher, MD
5:35 - 6:35	WINE AND BEER

ADJOURN



Bruce A. Perler graduated from Duke University and Duke University School of Medicine. In 2004 he received an MBA from the Carey School of Business of Johns Hopkins University. He completed his internship and residency at the Massachusetts General Hospital as well as a Clinical and Research Fellowship in Vascular Surgery at the Massachusetts General Hospital and Harvard Medical School.

Dr. Perler joined the faculty of the Johns Hopkins University School of Medicine in 1982 and was named the first recipient of the Julius H. Jacobson II, M.D. Endowed Chair in Vascular Surgery. He has served as Director of the Vascular Noninvasive Laboratory at the Johns Hopkins Hospital since 1982. In 1998 he established the Vascular Surgery Fellowship at the Johns Hopkins Hospital and served as its Director until 2009. Dr. Perler was named the Chief of the Division of Vascular Surgery & Endovascular Therapy at Johns Hopkins in January 2002. From 2013-2021, he served as the Vice-Chair for Clinical Operations and Financial Affairs for the Department of Surgery. Dr. Perler has received the Outstanding Faculty Teaching Award from the surgical house staff at Johns Hopkins.

He has edited or co-edited 5 textbooks, including Rutherford's Textbook of Vascular Surgery and Endovascular Therapy, 9th, 10th and 11th Editions. He has authored roughly 300 medical journal articles and textbook chapters on the diagnosis and treatment of the entire spectrum of circulatory diseases. He served as the Co-Editor of the Journal of Vascular Surgery, as well as being the co-founder and Co-Editor of the Journal of Vascular Surgery: Venous & Lymphatic Disorders and the Journal of Vascular Surgery Cases. He has also served on the Editorial Boards of Vascular and Endovascular Surgery, Vascular, and the Annals of Vascular Surgery. He has delivered nearly 400 lectures as a faculty member at national and international symposia and postgraduate courses, and as a Visiting Professor.

Dr. Perler held several leadership positions in vascular surgery, including President of the Society for Vascular Surgery (SVS) and Chair of the SVS Foundation. Dr. Perler has also served as President of the Southern Association for Vascular Surgery, the Eastern Vascular Society, and the Chesapeake Vascular Society. In 2021 he received the Lifetime Achievement Award from the Southern Association for Vascular Surgery and has been selected to receive the 2025 Lifetime Career Achievement Award from the International Symposium on Endovascular Therapy.

Dr. Perler has served as the Associate Executive Director of the American Board of Surgery for Vascular Surgery, and from 2019-2024 he served as the Vice President of the American Board of Surgery. He has served since 1989 as a Consultant to the Circulatory Devices Panel, Center for Devices and Radiologic Health of the Food and Drug Administration.

